NCT07477548 2026-03-17
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Yonsei University
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT07435584 2026-02-27
EVER-RECODE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT07407517 2026-02-12
POLARIS
Fudan University
Phase 3 Not yet recruiting
NCT07340541 2026-02-09
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07218575 2025-10-20
Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Boston Children's Hospital
Phase 2/3 Not yet recruiting
NCT06994572 2025-05-29
Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma
Captor Therapeutics S.A.
Phase 1 Not yet recruiting
NCT06682611 2024-11-12
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2 Not yet recruiting
NCT06561022 2024-08-19
abemaSNF1/3
Fudan University
Phase 2 Not yet recruiting
NCT06301386 2024-03-08
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
Fudan University
Phase 2 Not yet recruiting